NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.93% of ...

SELLAS Life Sciences Group has announced positive data from preclinical studies identifying the ASXL1 mutation as a significant predictor of response to SLS009, a selective cyclin-dependent kinase ...

A new option is available for mental health crises in Marion County, where a team of professionals from the Indianapolis ...

SELLAS Life Sciences will hold a corporate update call on January 8, 2025, discussing its 2025 outlook and clinical developments. SELLAS Life Sciences Group, Inc. announced it will hold a ...

State Street Corp raised its stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) by 30.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 174,529 shares of the ...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling ...

“We are highly encouraged by the emerging data, which continue to show the potential of SLS009 to transform outcomes of these heavily pretreated AML patients,” said Angelos Stergiou, MD, ScD h.c., ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...